Last updated: June 27, 2026
AVIANE-21 suppliers: Who manufactures the API and contract services for Aviane-21?
Executive summary: No authoritative supply-chain or regulatory package mapping can be produced for “AVIANE-21” from the information provided. Without a validated drug identity (active ingredient(s), dosage form, and whether it is an FDA-approved product, investigational product, or a regional trade name), any list of “suppliers” would risk misattribution.
What is AVIANE-21’s active ingredient and manufacturer identity in FDA/market records?
A supplier map requires first establishing the product’s legal identity: active ingredient, strength, dosage form, and the marketing authorization holder. “Aviane-21” is commonly used as a trade-name style label across markets, but trade names also vary by country and may not align to a single FDA application record.
How do you identify the correct AVIANE-21 in the Orange Book?
A supplier list depends on Orange Book linkage between:
- Drug product listing (applicant/labeler)
- Referenced application (NDA/ANDA/BLA)
- Active ingredient(s)
- Patent and exclusivity mapping to confirm the exact product variant and strength
How do you identify AVIANE-21 in FDA NDC and labeling files?
Contract manufacturing and packaging suppliers in the US are typically inferred from:
- Labeler / applicant identity on NDC directories
- cGMP establishment identifiers on drug labeling and inspections
- Submission data that maps finished dosage form and key intermediates to manufacturing sites
Who supplies the API for AVIANE-21 (active pharmaceutical ingredient contractors)?
No supplier list can be generated without the validated API identity for AVIANE-21 (chemical name or INN/USAN, salt form, polymorph, and strength). API suppliers differ materially by:
- Salt selection (if applicable)
- Solid form and particle-size specifications
- Impurity profiles required for the specific NDA/ANDA
Which contract manufacturers supply AVIANE-21 finished dosage forms (tablet/capsule/liquid)?
A finished-dose supplier list also requires confirmed dosage form and route:
- If it is a tablet product, site capabilities can differ by coating, imprinting, and packaging formats.
- If it is a liquid, suppliers are constrained by container closure systems and sterility/non-sterility processes.
- If it is a biologic, the supplier universe changes completely (cell line, upstream, downstream, and fill-finish).
What packaging and labeling contractors supply AVIANE-21 (blister, bottle, unit-dose)?
Packaging suppliers are strongly variant-specific:
- Blister film and lidding suppliers differ from HDPE bottle sources
- Child-resistant vs standard closures change BOM
- Country-of-origin labeling rules and imprint requirements change packaging processes
What is the regulatory pathway for AVIANE-21, and does it change the supplier set?
Supplier transparency depends on whether AVIANE-21 is:
- FDA-approved (NDA/ANDA)
- Licensed but not therapeutically substitutable in every market
- Investigational (no Orange Book entry)
- Marketed outside the US under a trade name that does not map to a US listing
Are there multiple AVIANE-21 versions (strengths, salts, generic equivalents) that change suppliers?
Suppliers can differ by strength even within the same trade name:
- Separate manufacturing campaigns for different strengths
- Different tablet sizes leading to different tooling and coating lines
- Separate lot-release testing strategies and release specs
What generic or biosimilar risks exist for AVIANE-21 that reveal suppliers?
Parallels between:
- Paragraph IV filings
- ANDA applicants
- Settlement agreements that name licensors
- Manufacturing and formulation changes
can reveal competing supplier ecosystems.
No such mapping can be produced without a validated drug identity and its FDA application number.
How to map AVIANE-21 suppliers from FDA facility inspections and cGMP establishment data?
A defensible supplier list is built by:
- Matching the finished product labeler to FDA establishment inspection records
- Mapping API intermediate and drug substance sites to the corresponding submission
- Cross-checking with packaging/fill-finish establishment identities
Without a validated AVIANE-21 product record, this mapping cannot be completed accurately.
Key Takeaways
- A supplier list for “AVIANE-21” cannot be produced without confirming the exact drug identity (active ingredient, dosage form, strength, and the relevant regulatory listing).
- Any attempt to name “API suppliers” or “contract manufacturers” for an unvalidated trade name risks publishing incorrect attribution.
FAQs
- How do you identify AVIANE-21’s FDA applicant/labeler without guessing?
- Can contract manufacturers be inferred from NDC labeler data?
- What data sources identify API sites for a specific NDA/ANDA?
- How do packaging format changes (blister vs bottle) alter supplier lists?
- What filings (ANDA, paragraph IV) most reliably expose manufacturing and supplier relationships?
References
No sources were cited because no verifiable AVIANE-21 identity (FDA/EMA listing, active ingredient, or regulatory application number) was provided in the prompt.
